Beqvez (fidanacogene elaparvovec-dzkt)
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and coverage criteria for a single intravenous dose of Beqvez for adults with moderate to severe congenital factor IX deficiency. It applies to BCBS Kansas members and BCBS Kansas-administered self-insured plans, subject to member benefits, contracts, and applicable mandates.
The policy updated administrative wording for initial and renewal authorization periods, initial criteria, and prior authorization validity.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.